Skip to main content
SpringerLink
Log in

Medical Therapy of Cushing's Disease

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Surgical excision of an ACTH-producing pituitary tumor is the optimal therapy for Cushing's disease. However, medical therapy may have either a primary or adjunctive role if the patient cannot safely undergo surgery, if surgery fails, or if the tumor recurs. When medication is the only therapy, a major disadvantage is the need for lifelong therapy; in general, recurrence follows discontinuation of treatment. These compounds work through three broad mechanisms of action. “Neuromodulatory” compounds modulate corticotropin (ACTH) release from a pituitary tumor, steroidogenesis inhibitors reduce cortisol levels by adrenolytic activity and/or direct enzymatic inhibition and glucocorticoid antagonists block cortisol action at its receptor.

In general, neuromodulatory compounds (bromocriptine, cyproheptidine, somatostatin and valproic acid) are not very effective agents for Cushing's disease. Treatment with a glucocorticoid antagonist and radiation therapy has been reported on a single patient only. Steroidogenesis inhibitors, including mitotane, metyrapone, ketoconazole, and aminoglutethimide, are the agents of choice for medical therapy of Cushing's disease. In general, ketoconazole is the best tolerated of these agents and is effective as monotherapy in about 70% of patients. Mitotane and metyrapone may be effective as single agents, while aminoglutethimide generally must be given in combination. The intravenously-administered etomidate may used when patients cannot take medications by mouth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tomita A, Suzuki S, Hara I, Oiso Y, Mizuno S, Yogo H, Kuwayama A, Kageyama N. Follow-up study on treatment in 27 patients with Cushing's disease: Adrenalectomy, transsphenoidal adenomectomy and medical treatment. Endocrinol Jpn 1981;28:197–205.

    Google Scholar 

  2. Ambrosi B, Gaggini M, Secchi F, Faglia G. Lack of effect of antiserotoninergic and/or dopaminergic treatment in patients with pituitary-dependent Cushing's syndrome. Horm Metab Res 1979;11:318–319.

    Google Scholar 

  3. Krieger DT, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing's disease. N Engl J Med 1975;293:893–896.

    Google Scholar 

  4. Tyrrell JB, Brooks RM, Forsham PH. More on cyproheptadine. N Engl J Med 1976;295:1137–1138.

    Google Scholar 

  5. Copinschi G, Goldstein J, Virasoro E, Franckson JKM. Lack of effect of cyproheptidine in Cushing's disease and in Nelson's syndrome (abstr). Acta Endocrinol (Copenh) 1977;312:ob-Suppl 130J:90.

    Google Scholar 

  6. Sonino N, Fava GA, Fallo F, Franceschetto A, Belluardo P, Boscaro M. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary 2000;3:55–59.

    Google Scholar 

  7. Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev 1993;14:443–458.

    Google Scholar 

  8. Nussey SS, Price P, Jenkins JS, Altaher AR, Gillham B, Jones MT. The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome. Clin Endocrinol (Oxf) 1988;28:373–380.

    Google Scholar 

  9. Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J, Muller OA. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 1994;130:125–131.

    Google Scholar 

  10. Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 1989;120:760–766.

    Google Scholar 

  11. Woodhouse NJ, Dagogo-Jack S, Ahmed M, Judzewitsch R. Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing's syndrome. Am J Med 1993;95:305–308.

    Google Scholar 

  12. Vignati F, Loli P. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J Clin Endocrinol Metab 1996;81:2885–2890.

    Google Scholar 

  13. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 1999;22:860–865.

    Google Scholar 

  14. Potts GO, Creange JE, Harding HR, Schane HP. Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 1978;32:257–267.

    Google Scholar 

  15. Santen RJ, Misbin RI. Aminoglutethimide: Review of pharmacology and clinical use. Pharmacotherapy 1981;1:95–120.

    Google Scholar 

  16. Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev 1986;7:409–420.

    Google Scholar 

  17. Hutter AM, Kayhoe DE. Adrenal cortical carcinoma: Results of treatment with o, p?-DDD in 138 patients. Am J Med 1966;41:581–592.

    Google Scholar 

  18. Gorden P, Becker C, Levey GS, Roth J. Efficacy of aminoglutethimide in the ectopic ACTH syndrome. J Clin Endocrinol 1968;28:921–923.

    Google Scholar 

  19. Verhelst JA, Trainer PJ, Howlett TA, et al. Short-and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol 1991;35:169–178.

    Google Scholar 

  20. Orth DN. Metyrapone is useful only as adjunctive therapy in Cushing's disease (editorial). Ann Intern Med 1978;89:128–130.

    Google Scholar 

  21. Misbin R, Canary J, Willard D. Aminoglutethimide in the treatment of Cushing's syndrome. J Clin Pharmacol 1976;16:645–651.

    Google Scholar 

  22. Zachman M, Gitzelman RP, Zagalak M, Prader A. Effect of aminoglutethimide on urinary cortisol and cortisol metabolites in adolescents with Cushing's syndrome. Clin Endocrinol 1977;7:63–71.

    Google Scholar 

  23. Horky K, Kuchel O, Gregvoria I, Starka L. Qualitative alterations in urinary 17-ketosteroid excretion during aminoglutethimide administration. J Clin Endocrinol Metab 1969;29:297–301.

    Google Scholar 

  24. Hart MM, Swackhamer ES, Straw JA. Studies on the site of action of o, p?-DDD in the dog adrenal cortex: TNPH and corticosteroid precursor stimulation of o, p?-DDD inhibited steroidogenesis. Steroids 1971;17:575–586.

    Google Scholar 

  25. 25. Ojima M, Saitoh M, Itoh N, et al. The effects of o, p-DDD on adrenal steroidogenesis and hepatic steroid metabolism. Nipon Naibunpi Gakkai Zasshi Folia Endocrinol Jpn 1985;61:168–178.

    Google Scholar 

  26. Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 1973;223:1109–1112.

    Google Scholar 

  27. Guttierrez ML, Crooke ST. Mitotane (o, p?-DDD) in inoperable adrenocortical carcinoma. Cancer Treat Rev 1980;7:49–55.

    Google Scholar 

  28. Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing's disease by o, p?-DDD: Survey of 62 cases. N Engl J Med 1979;300:459–464.

    Google Scholar 

  29. Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA. Sustained remission of Cushing's diseaes with mitotane and pituitary irradiation. Ann Intern Med 1980;92:613–619.

    Google Scholar 

  30. Leiba S, Weinstein R, Shindel B, et al. The protracted effect of o, p?-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol 1989;50:49–53.

    Google Scholar 

  31. Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o, p?-DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol 1989;31:51–57.

    Google Scholar 

  32. Bledsoe T, Island DP, Ney RL, Liddle GW. The effect of o, p?-DDD on cortisol and 6 beta hydroxycortisol secretion and metabolism in man. J Clin Endocrinol Metab 1971;24:1303–1311.

    Google Scholar 

  33. Dewis DC, Bullock DE, Earnshaw R, Kelly WF. Experience with trilostane in the treatment of Cushing's syndrome. Clin Endocrinol 1983;18:533–540.

    Google Scholar 

  34. Ross WM, Evered DC, Hunter P, et al. Treatment of Cushing's disease with adrenal blocking drugs and megavoltage therapy to the pituitary. Clin Radiol 1979;30:149–153.

    Google Scholar 

  35. Fishman LM, Liddle GW, Island DP, et al. Effects of aminoglutethimide on adrenal function in man. J Clin Endocrinol Metab 1967;27:481–490.

    Google Scholar 

  36. Thoren M, Adamson U, Sjoberg HE. Aminoglutethimide and metyrapone in the management of Cushing's syndrome. Acta Endocrinol (Copenh) 1985;109:451–457.

    Google Scholar 

  37. Jeffcoate WJ, Rees LH, Tomlin S, et al. Metyrapone in longterm management of Cushing's disease. Br J Med 1977;2:215–217.

    Google Scholar 

  38. Dickstein G, Lahav M, Shen-Orr Z, Edoute Y, Barzilai D. Primary therapy for Cushing's disease with metyrapone. JAMA 1986;255:1167–1169.

    Google Scholar 

  39. Donckier J, Burrin JM, Ramsay ID, Joplin GF. Successful control of Cushing's disease in the elderly with long term metyrapone. Postgrad Med J 1986;62:727–730.

    Google Scholar 

  40. Child DF, Burke CW, Burley DM, et al. Drug control of Cushing's syndrome: Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol (Copenh) 1976;82:330–341.

    Google Scholar 

  41. Schteingart DE, Conn JW. Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing's syndrome. J Clin Endocrinol Metab 1967;27:1657–1666.

    Google Scholar 

  42. Santen RJ, Misbin RI. Aminoglutethimide: Review of pharmacology and clinical use. Pharmacotherapy 1981;1:95–120.

    Google Scholar 

  43. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987;317:812–818.

    Google Scholar 

  44. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 1983;71:1495–1499.

    Google Scholar 

  45. Lamberts SW, Bons EG, Bruining HA, de Jong FH. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther 1987;240:259–264.

    Google Scholar 

  46. Jimenez Reina L, Leal-Cerro A, Garcia J, Garcia-Luna PP, Astorga R, Bernal G. In vitro effects of ketoconazole on corticotrope cell morphology and ACTH secretion of two pituitary adenomas removed from patients with Nelson's syndrome. Acta Endocrinol (Copenh) 1989;121:185–190.

    Google Scholar 

  47. Stalla GK, Stalla J, Huber M, Loeffler JP, Hollt V, vonWerder K, Muller OA. Ketoconazole inhibits corticotropic cell function in vitro. Endocrinology 1988;122:618–623.

    Google Scholar 

  48. Burrin JM, Yeo TH, Ashby MJ, Bloom SR. Effect of ketoconazole on adrenocorticotrophic hormone secretion in vitro and in vivo. J Endocrinol 1986;108:37–41.

    Google Scholar 

  49. Engelhardt D, Weber MM. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 1994;49:261–267.

    Google Scholar 

  50. Angeli A, Frairia R. Ketoconazole therapy in Cushing's disease. Lancet 1985;6;1(8432):821.

    Google Scholar 

  51. Boscaro M, Sonino N, Rampazzo A, Mantero F. Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing's disease before and after ketoconazole treatment. Clin Endocrinol (Oxf) 1987;27:461–467.

    Google Scholar 

  52. Lewis JH, Hyman JZ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Gastroenterology 1984;86:503–513.

    Google Scholar 

  53. Winquist EW, Laskey J, Crump M, Khamsi F, Shepherd FA. Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production. J Clin Oncol 1995;13:157–164.

    Google Scholar 

  54. Schulte HM, Benker G, Reinwein D, et al. Infusion of low dose etomidate: Correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990;70:1426–1430.

    Google Scholar 

  55. Drake WM, Perry LA, Hinds CJ, et al. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab 1998;83:3542–3544.

    Google Scholar 

  56. Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab 2001;86:4104–4108.

    Google Scholar 

  57. Nieman L, Chrousos G, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985;61:536–540.

    Google Scholar 

  58. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 2001;86:3568–3573.

    Google Scholar 

  59. Gaillard RC, Riondel A, Muller AF, et al. RU 486. A steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Proc Natl Acad Sci USA 1984;81:3879–3882.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA

    Lynnette K. Nieman

Authors
  1. Lynnette K. Nieman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nieman, L.K. Medical Therapy of Cushing's Disease. Pituitary 5, 77–82 (2002). https://doi.org/10.1023/A:1022308429992

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022308429992

Search

Navigation